MAR
MAR
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
3
$3.70M
Total Volume
$3.70M
3 transactions
Net Activity
$3.70M
Net selling
Sentiment Rating
Moderate DistributionCEO Conviction Index
No Recent Signal
Key Drivers
- •Heavy distribution: sales represent 100% of total transaction value.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
MAR has an insider buy conviction of 0%, compared to the Unknown sector buy average of 50%.
Marriott David S
13D Group Owning more than 10%
$1.23M total
Harrison Deborah Marriott
Member of 13(d) group
$1.23M total
Marriott J W Jr
13D Group Owning more than 10%, 10%
$1.23M total
Over the last 90 days, corporate insiders at MAR (MAR) engaged in a total of 3 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 3 were sales. The total volume of insider trading reached $3.70M.
The net insider activity for MAR shows a net selling bias of $3.70M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Marriott David S (13D Group Owning more than 10%), who traded 3.5K shares valued at $1.23M on Sep 25, 2026.
Quick Actions
Related News & Analyst Reports
Read original insights and educational research covering MAR and the Unknown sector.
The Biotech Executive Playbook: Tracking Clinical Phase SEC Filings
An empirical study on how clinical-stage biotech executives execute Form 4 open-market purchases ahead of trial data releases, outlining the regulatory gaps and alpha potential of clinical insider tracking.
Deciphering Form 5 Filings: Uncovering Annual Insider Gift Trades
A comprehensive guide to SEC Form 5 filings, explaining how annual reports of gift shares, stock options, and non-open-market transactions signal insider sentiment.
The Quant Guide: Backtesting SEC Form 4 Cluster Buys for Alpha
A rigorous quantitative backtest of SEC Form 4 cluster buying activity, demonstrating how to isolate signal from noise and build portfolios that consistently outperform benchmarks.
a16z Capital Distributions vs. Open-Market Insider Buying: A 2026 Study
A 2026 empirical study comparing Andreessen Horowitz's in-kind share distributions to LPs against open-market insider purchases, revealing which signal better predicts 12-month price performance.
The Impact of Interest Rates on Insider Behavior: A Macro Analysis
When the Fed tightens, equity valuations fall, but insider purchase activity does not always follow the same pattern. This report examines three rate-hike cycles to show how rising rates affect the frequency and conviction of C-suite stock buys.
Institutional Ownership vs. Insider Trading: Understanding the Data Flow
High institutional ownership reduces information asymmetry, but does it also reduce the predictive power of insider trades? This analysis tests whether stocks with more than 70% institutional ownership show weaker Form 4 signal performance.
FAQs About MAR Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for MAR.